SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The project is a derivative of Fartcoin. The Fartcoin deployer has deployed this token because the President at Bone Fide Wealth tweeted about "A client just called and asked me if there’s going to be a Fartcoin ETF this year." Since the Elon narrative is has been running this one has come to existence. The token is following different narratives like Fartcoin, SPX500 and other big memes following the Trump narrative.

Elon Trump Fart

ETF500.X is trending as community members rally around the self-proclaimed "first ETF on Solana," with many highlighting the strong community and encouraging others to "load up" for a potential "meme season." Despite some skepticism, supporters express confidence in the project's long-term potential and encourage holding through market fluctuations. The project's branding and community-driven nature appear to be key talking points.

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

BioAffinity Technologies Inc

BioAffinity Technologies ($BIAF) is trending due to positive case studies highlighting the effectiveness of its CyPath Lung test for early lung cancer detection, potentially reducing unnecessary biopsies. The stock's low float and recent reverse split are fueling community discussions about a potential squeeze, with some anticipating a run to higher price levels. Bullish sentiment revolves around the company's cancer detection technology and its potential for a large market opportunity.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses a mix of factors, including analyst upgrades citing AI and robotaxi potential, and debates over valuation. Some traders point to technical signals and anticipate further upward movement, while others express concerns about sales figures and potential pullbacks. Additionally, discussions around Elon Musk's involvement in the Epstein files are circulating.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors assess its future growth potential amid discussions around government funding and domestic rare earth production. Community members are weighing the impact of strategic partnerships and production gains, while also debating potential connections to political figures. Some traders are closely watching technical indicators and options activity for potential entry points, while others express concerns about short-term volatility.

Electronic Arts, Inc. engages in the development, marketing, publication, and distribution of games, content, and services for game consoles, PCs, mobile phones, and tablets. The company develops and publishes games and services across various genres, such as sports, first-person shooter, action, role-playing, and simulation primarily under the Battlefield, The Sims, Apex Legends, Anthem, Need for Speed, and Plants v. Zombies brands, and license games, including FIFA, Madden NFL, and Star Wars brands. The firm also provides advertising services and licenses its games to third parties to distribute and host its games. It markets and sells its games and services through digital distribution channels, as well as through retail channels, such as mass-market retailers, electronics specialty stores, and game software specialty stores. The company was founded by William M. Hawkins III and William Gordon in 1982 and is headquartered in Redwood City, CA.

Electronic Arts, Inc.

Electronic Arts is trending amid reports of a potential leveraged buyout valued at $50 billion, backed by investors like Silver Lake and Saudi Arabia's Public Investment Fund, leading to a surge in stock price and trading halts. The community is discussing the potential buyout price and impact on other video game stocks, while also reflecting on the company's past performance and future prospects. Some investors express concerns about debt, the quality of games, and the implications for the gaming sector as a whole.

BTQ Technologies Corp

BTQ is trending as investors discuss the potential impact of a $300 million registration for dilution after its NASDAQ debut, with some expressing disappointment and others viewing it as a long-term buying opportunity. Community members are debating the company's valuation and revenue prospects in the quantum cybersecurity space, while awaiting news about Robinhood availability. Some investors remain bullish, citing a deal with Danal and the potential for BTQ to become a leader in quantum-safe technology.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as community members speculate about potential partnerships with Apple and TSMC and how this might impact the company's growth and stock value. Traders are actively discussing potential price movements, with many eyeing the $40 mark, and attributing the stock's momentum to government support for domestic chip manufacturing. Some investors believe that Intel is undervalued compared to its peers, while others suggest caution, pointing to technical indicators and potential overbought conditions.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as the community focuses on its potential within the DEX and DeFi space, particularly its trending status and potential price movements. Bullish sentiment seems to be fueled by discussions around breaking resistance levels and predictions of continued upward momentum. Some traders are drawing comparisons to similar projects and anticipating substantial growth, while others urge caution and highlight the inherent volatility.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals ($CRNX) is trending as the community discusses its potential, driven by the recent FDA approval of Palsonify for acromegaly. Community members are actively discussing the steady share price post-approval and anticipating a second leg up, with some suggesting the stock could reach triple digits in the coming year. Bullish sentiment is fueled by the drug's clean label, expansion into Europe, and convenience for patients, while others point to high institutional ownership and potential for a short squeeze.

Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV.

Aqua Metals Inc

AQMS is trending due to recent momentum and speculative interest in low-float stocks, particularly within the lithium sector. The community is actively discussing the stock's potential for a significant breakout and potential short squeeze, drawing comparisons to other high-flying stocks in the sector. Aqua Metals' participation in an upcoming battery show and a focus on critical minerals may be contributing to the heightened interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail buzz around Taysha Gene Therapies Inc surged Tuesday after the company released new clinical results from its TSHA-102 trial for Rett syndrome.Taysha Gene Therapies shares dipped 0.2% to close at $2.78 on Tuesday, before gaining 0.7% to $2.8 in after-hours trading.During its Reveal Phase 1/2 trials, the company presented recent cohort data for TSHA-102, which administered high and low doses to adolescent,&nbsp;adult, and pediatric patients&nbsp;through lumbar intrathecal delivery.Caregiver-reported improvements in developmental milestones supported Taysha’s alignment with the U.S. Food and Drug Administration (FDA) on the primary endpoint for the pivotal Part B trial of TSHA-102.Previously released preclinical data demonstrated broad biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions in non-human primates.Taysha will present these findings in three oral presentations and a poster session at the 2025 International Rett Syndrome Foundation (IRSF) Scientific Meeting in Boston, June 9-11.Canaccord Genuity raised its price target on Taysha shares to $11 from $9, while maintaining a ‘Buy’ rating, citing positive longer-term low-dose follow-up and initial high-dose data disclosed by the company.&nbsp;The research firm also increased its assigned probability of success (POS) for TSHA-102 to 75% from 50%.Canaccord’s updated model also factored in the recently announced approximately $200 million offering via a combination of shares and prefunded warrants.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that it is unusual for a stock to increase during an offering, welcoming Taysha as an exception.&nbsp;<stembedurl>https://stocktwits.com/KING_OF_BIO/message/616691905</stembedurl>Another user highlighted that all price targets for Taysha have been raised.<stembedurl>https://stocktwits.com/strategicmind/message/616553737</stembedurl>The stock has risen 50.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program. 

Equity

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Trump Rally Fizzles: Futures Drop As Dollar, Yields Extend Surge

Trump Rally Fizzles: Futures Drop As Dollar, Yields Extend Surge

 The torrid five-day rally that pushed the S&P 500 to its 51st record close above 6,000 on Monday has finally reversed...

Analysts Are Bullish on Top Healthcare Stocks: Beam Therapeutics (BEAM), Taysha Gene Therapies (TSHA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Beam Therapeutics (BEAM Research Report) and Taysha Gene Therapies...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Taysha Gene Therapies Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

TSHA
Taysha Gene Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TSHA News

TSHA Taysha Gene Therapies Inc